Trial reportThe world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry2010
Patients' preference for olanzapine orodispersible tablet compared with conventional oral tablet in a multinational, randomized, crossover study.
Trial report in The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00324051 (PREFERENCE), which is not on this map. Cited by 13 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
PREFERENCE: 12-Week Open Label Trial On Olanzapine Orodispersible Tablet Vs. Oral Olanzapine Preference Study
Who cites it
13 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- The impacts of antipsychotic medications on eating-related outcomes: A mixed methods systematic review.PloS one · 2025Pooled it
- Eating cognitions, emotions and behaviour under treatment with second generation antipsychotics: A systematic review and meta-analysis.Journal of psychiatric research · 2023Pooled it
- Almost all antipsychotics result in weight gain: a meta-analysis.PloS one · 2014 · on this mapPooled it
- Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychotics.International clinical psychopharmacology · 2015Trial
- Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study.International clinical psychopharmacology · 2014Trial
- The Role of Pharmaceutical Compounding in Promoting Medication Adherence.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Comparative Effectiveness of Second Generation Long-acting Injectable Antipsychotics Based on Nationwide Database Research in Hungary: An Update.Schizophrenia bulletin open · 2022Article
- Patient Centric Pharmaceutical Drug Product Design-The Impact on Medication Adherence.Pharmaceutics · 2020Review
- Comparative effectiveness of second generation long-acting injectable antipsychotics based on nationwide database research in Hungary.PloS one · 2019Article
- Comparison of clinical outcomes with orodispersible versus standard oral olanzapine tablets in nonadherent patients with schizophrenia or bipolar disorder.Patient preference and adherence · 2017Article
- An in vitro analysis of disintegration times of different formulations of olanzapine orodispersible tablet: a preliminary report.Drugs in R&D · 2013Article
- Orally disintegrating olanzapine review: effectiveness, patient preference, adherence, and other properties.Patient preference and adherence · 2012Article
- Olanzapine orally disintegrating tablet: a review of efficacy and compliance.CNS neuroscience & therapeutics · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe aim of this study was to compare patients' preference for olanzapine orodispersible tablet (ODT) with oral conventional tablet (OCT).
methodsA 12-week randomized, crossover, multinational, open-label study was conducted to estimate the proportion of patients preferring ODT or OCT. Outpatients with stable schizophrenia on OCT monotherapy were randomly assigned 1:1 to ODT or OCT. Compliance and drug attitude were measured using the Drug Attitude Inventory (DAI-10) and Medication Adherence Form (MAF) scales; tolerability and safety by Association for Methodology and Documentation in Psychiatry (AMDP-5) questionnaire and adverse event summary.
resultsA total of 175 patients answered a preference question: 106 (61%) preferred ODT and 48 (27%) preferred OCT (P<0.001 adjusted for treatment sequence); 21 (12%) expressed no preference. There was no significant change in DAI-10 with either formulation. MAF was above 75% in 94% vs. 93% of patients on ODC and OCT, respectively. Compliance as measured by tablet count was above 98% on both formulations. The adverse event profiles did not differ between formulations. Mean weight increase over 6 weeks on ODT was 0.8 kg and on OCT was 0.6 kg.
conclusionsGiven the importance of patients' preference for treatment planning and success, the ODT formulation should be routinely considered as a treatment option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.